The targets advancing through your pipeline have been validated by your team. Have they been validated against everything your team cannot see?
Independent mechanism validation for pipeline decisions, portfolio governance, and program advancement reviews.
The Tools Your Team Already Uses Cannot Answer the Question That Matters Most
Internal teams, licensed databases, AI platforms, and consultants each solve part of the problem. None of them solve the part that matters most at a governance decision — the cross-reference against what your organization cannot see.
| Resource | What It Does | Limitation |
|---|---|---|
| Internal Teams | Program-specific analysis and experimental validation | Cannot detect parallel programs or emerging contradictions |
| Licensed Databases | Aggregate published findings and pathway associations | Do not capture unpublished or evolving research signals |
| Consultants & KOLs | Expert interpretation within defined domains | Limited to individual knowledge and accessible literature |
| AI & Molecular Modeling | Predict and simulate biological interactions | Do not verify whether underlying assumptions hold |
| Individual Programs | Deep development within a specific target or indication | Lack cross-program and cross-institutional perspective |
These approaches provide prediction, simulation, and interpretation. They do not provide independent validation of mechanism strength across competing biological explanations, datasets, and active parallel programs.
The Decision Moments Where Internal Analysis Is Not Enough
Independent target validation applies at specific points in the pipeline — as a structured external reference before commitment is made.
- Evaluation of new targets entering the pipeline at any stage
- Program continuation or termination reviews at preclinical and early clinical gates
- Internal portfolio prioritization and resource allocation decisions
- Indication expansion assessment prior to governance committee review
- Partnership, licensing, or acquisition evaluation of external assets
- Documentation of scientific rationale for regulatory submissions
Six Dimensions of Mechanism Credibility Your Governance Committee Will Assess
Each dimension addresses a specific question that internal analysis raises but cannot independently answer.
Driver vs. Passenger
Is the target a primary cause of disease biology or a correlated downstream signal? The single most important mechanism question at every pipeline gate — documented with cross-referenced evidence, not internal assertion.
Target Centrality
Does this target occupy a structurally essential position in the relevant pathway? Mathematical centrality assessment, not literature familiarity. A target that appears in pathway diagrams is not necessarily a mechanistically essential node.
Cross-Dataset Reproducibility
Does the biological signal hold across independent studies and modalities? Single-study observations driving pipeline decisions are the highest-risk element of early program advancement. Quantified with a dataset-level breakdown.
Contradiction Detection
What conflicting evidence exists outside your organization's literature synthesis? Contradictions from active parallel investigations that haven't yet published are the most dangerous gaps in any mechanism defense. Surfaced before governance review, not during it.
Evidence Gap Mapping
Which mechanistic links does your program depend on that remain unvalidated? These are the questions a governance committee, regulatory reviewer, or due diligence partner will ask. Identifying them before those moments gives you the choice of how to address them.
Competitive & Parallel Activity
What parallel programs exist in your target space — including those not yet visible in publication databases? Signal from active research programs that haven't published, cross-referenced against your target through the reasoning layer.
The Signal Your Organization Structurally Cannot Access
The most consequential differentiator in this report is the cross-reference against active scientific investigation that has not yet been published.
Researchers globally contribute structured research hypotheses to Skygenic's continuously evolving reasoning layer — linking their active investigations to experimental data and evolving their reasoning as evidence changes. Their identities are never revealed. Their unpublished data is never exposed.
What the reasoning layer captures is the structure of their scientific reasoning — and that structure contains signals invisible to any database, any consultant, and any internal team.
- Active parallel investigations in adjacent disease areas
- Competing mechanism hypotheses being tested in other programs
- Convergence signals emerging from independent fields simultaneously
No team, CRO, or platform can replicate this view — because the data exists only here.
Independent Validation Functions as Scientific Due Diligence
Freedom to Operate exists because IP risk cannot be assessed by the party that created it. The same logic applies to mechanism risk.
Pharmaceutical development applies multiple forms of due diligence to every program: clinical, regulatory, commercial, and intellectual property. Independent scientific validation addresses the underlying biological assumptions that connect all of these layers. A program's regulatory pathway and commercial model are contingent on the mechanism being correctly identified, characterized, and defended.
In the absence of independent validation, the burden of proof rests entirely on internal interpretation — leaving technical gaps exposed to external scrutiny.
How It Works
One engagement. No platform subscription. No integration with existing infrastructure.
You provide a hypothesis statement, your target or mechanism of interest, and any datasets your program has generated. The report is assessed against the full reasoning layer — cross-referencing public evidence, active network signal, and your own data — and returned as a structured validation report.
Scoped per engagement. Comparable to external scientific diligence and advisory fees.
Related reports
Explore adjacent validation types within your decision workflow.
View all Pharma validation reports for the full cluster overview and internal navigation.
Strategic Audit
Request a target validation report
Independent mechanism validation for pharmaceutical target assessment, pipeline prioritization, and portfolio governance. Third-party scientific analysis for decisions that carry downstream clinical and financial risk.